AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7966668 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral prostatectomy (ambient temperature irrigant at 21C)
Number of subjects: 52
Study 3334952 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention with four messages during radiation therapy
Number of subjects: 84
Study 3334952 — intervention group
Group type: COMPARATOR
Intervention: Routine information provided to control patients
Number of subjects: 84
Study 3334952 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention
Number of subjects: 84
Study 30957167 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin 300 mg IV every 12 hours (Study 302); 300 mg IV every 12 hours for 3 days, then 450 mg orally every 12 hours (Study 303)
Number of subjects: 1510
Study 30957167 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Number of subjects: 1510
Study 30957167 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin/aztreonam
Number of subjects: 1510
Study 29173037 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-sex intervention (including women)
Number of subjects: 262
Study 29173037 — intervention group
Group type: COMPARATOR
Intervention: All-male intervention
Number of subjects: 262
Study 24661576 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylo-oligosaccharides (XOS) 8 g/d
Number of subjects: 0
Study 24661576 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis Bi-07 109 CFU/d
Number of subjects: 0
Study 24661576 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylo-oligosaccharides (XOS) 8 g/d and Bifidobacterium animalis subsp. lactis Bi-07 109 CFU/d
Number of subjects: 0
Study 22222473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5-3.5 vol.%) and Remifentanil (0-12 ng/ml)
Number of subjects: 40
Study 22222473 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed C50(O) Hierarchical model
Number of subjects: 40
Study 22222473 — intervention group
Group type: EXPERIMENTAL
Intervention: Minto model
Number of subjects: 40
Study 22222473 — intervention group
Group type: EXPERIMENTAL
Intervention: Greco model
Number of subjects: 40
Study 20500891 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme delivered to GPs and care staff in the intervention groups.
Number of subjects: 351
Study 20500891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education intervention).
Number of subjects: 351
Study 18062108 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 25
Study 18062108 — intervention group
Group type: COMPARATOR
Intervention: Modified Widman flap surgery
Number of subjects: 25
Study 15861196 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane bags
Number of subjects: 0
Study 15861196 — intervention group
Group type: COMPARATOR
Intervention: Control (no polyurethane bags)
Number of subjects: 0
Study 12370798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin 200 IU daily for 3 months
Number of subjects: 260
Study 12370798 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 260
Study 10213650 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (10 mg oral dose pre-HD)
Number of subjects: 11
Study 10213650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool dialysate (35.5 degrees C)
Number of subjects: 11
Study 10213650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (midodrine 10 mg and dialysate temperature 35.5 degrees C)
Number of subjects: 11
Study 10213650 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no treatment)
Number of subjects: 11
Study 7788948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg)
Number of subjects: 36
Study 7788948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 36
Study 7788948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1973547 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 71
Study 1973547 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 71
Study 6111161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.8 mg p. o.)
Number of subjects: 0
Study 6111161 — intervention group
Group type: COMPARATOR
Intervention: Beta-receptor-blocker (Mepindolol)
Number of subjects: 0
Study 6111161 — intervention group
Group type: COMPARATOR
Intervention: Combination of beta-receptor-blocker (Oxprenolol) and calcium-antagonist (Fendiline)
Number of subjects: 0
Study 6111161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0
Study 31324842 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and carbohydrate (CHO + CAFF)
Number of subjects: 0
Study 31324842 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate only (CHO)
Number of subjects: 0
Study 28280975 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring (NH) eccentric strength training combined with static stretching for 6 weeks
Number of subjects: 20
Study 28280975 — intervention group
Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 20
Study 25994567 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA therapy
Number of subjects: 60
Study 25994567 — intervention group
Group type: COMPARATOR
Intervention: corn oil therapy (control)
Number of subjects: 60
Study 22854015 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Disclosure Protocol (writing about stressful life experiences)
Number of subjects: 122
Study 22854015 — intervention group
Group type: COMPARATOR
Intervention: Writing about positive life experiences
Number of subjects: 122
Study 22854015 — intervention group
Group type: COMPARATOR
Intervention: Writing about plans for the day
Number of subjects: 122
Study 19681930 — intervention group
Group type: EXPERIMENTAL
Intervention: BoneCeramic®
Number of subjects: 10
Study 19681930 — intervention group
Group type: COMPARATOR
Intervention: Control (naturally healed sockets)
Number of subjects: 10
Study 19131417 — intervention group
Group type: EXPERIMENTAL
Intervention: Test characteristics (sensitivity and specificity)
Number of subjects: 1502
Study 19131417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intended clinical management (discontinue erythromycin or discharge)
Number of subjects: 1502
Study 19131417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intended clinical management (hospitalisation)
Number of subjects: 1502
Study 17381356 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous laser ablation (PLA)
Number of subjects: 62
Study 17381356 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine therapy (LT4)
Number of subjects: 62
Study 17381356 — intervention group
Group type: COMPARATOR
Intervention: Follow-up
Number of subjects: 62
Study 16935904 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha
Number of subjects: 13
Study 16935904 — intervention group
Group type: COMPARATOR
Intervention: Epoetin-beta
Number of subjects: 13
Study 16935904 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha and Epoetin-beta
Number of subjects: 13
Study 12749490 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 644
Study 12749490 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ITNs)
Number of subjects: 644
Study 10487974 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant (Vitamin E)
Number of subjects: 0
Study 10487974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8712656 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing for 2 hours
Number of subjects: 72
Study 8712656 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing for 24 hours
Number of subjects: 72
Study 1928883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric treatment (simulated descent of 1,432 m (4,600 ft) in a hyperbaric chamber pressurized to 120 mm Hg (2.3 PSI) above ambient pressure)
Number of subjects: 24
Study 1928883 — intervention group
Group type: COMPARATOR
Intervention: Oxygen treatment (4 L of oxygen given by facemask)
Number of subjects: 24
Study 6761082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole (500 mg every 12 h i.v. or orally)
Number of subjects: 140
Study 6761082 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (600 mg every 8 h i.v.)
Number of subjects: 140
Study 6761082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole
Number of subjects: 140
Study 6761082 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 140
Study 31289059 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture as an adjunctive therapy to routine medical care
Number of subjects: 30
Study 31289059 — intervention group
Group type: COMPARATOR
Intervention: Routine pain management without acupuncture
Number of subjects: 30
Study 28492439 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar block with 0.5% ropivacaine (n = 13)
Number of subjects: 28
Study 28492439 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia plus normal saline (n = 15)
Number of subjects: 28
Study 25195191 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 0
Study 25195191 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 0
Study 25195191 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 15 mg
Number of subjects: 0
Study 25195191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23234802 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol (400 mg)
Number of subjects: 600
Study 23234802 — intervention group
Group type: COMPARATOR
Intervention: Control (mannitol 50 mg)
Number of subjects: 600
Study 21241954 — intervention group
Group type: EXPERIMENTAL
Intervention: CLON‐XR 0.2 mg/day
Number of subjects: 236
Study 21241954 — intervention group
Group type: EXPERIMENTAL
Intervention: CLON‐XR 0.4 mg/day
Number of subjects: 236
Study 21241954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 19229716 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music intervention (50 minutes, 3 times per week for 5 weeks)
Number of subjects: 20
Study 19229716 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study 16837877 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued exercise participation after a 6-week walking program
Number of subjects: 23
Study 16837877 — intervention group
Group type: COMPARATOR
Intervention: 6-week walking program at 50% heart rate reserve
Number of subjects: 23
Study 15097154 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV 1200 mg twice daily
Number of subjects: 31
Study 15097154 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r 300/200 mg twice daily
Number of subjects: 31
Study 15097154 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r 1200/200 mg twice daily
Number of subjects: 31
Study 15097154 — intervention group
Group type: COMPARATOR
Intervention: TPV 1200 mg
Number of subjects: 31
Study 15097154 — intervention group
Group type: COMPARATOR
Intervention: TPV/r 300/200 mg
Number of subjects: 31
Study 11069312 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide for inducing remission in active Crohn's disease
Number of subjects: 12
Study 11069312 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide for reducing corticosteroid-related adverse events
Number of subjects: 12
Study 11069312 — intervention group
Group type: COMPARATOR
Intervention: Budesonide for preventing relapse in medically induced remission
Number of subjects: 12
Study 11069312 — intervention group
Group type: COMPARATOR
Intervention: Budesonide for preventing endoscopic recurrence in surgically induced remission
Number of subjects: 12
Study 11069312 — intervention group
Group type: COMPARATOR
Intervention: Budesonide in long-term treatment for corticosteroid-related adverse effects
Number of subjects: 12
Study 9262887 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial sevens test
Number of subjects: 631
Study 9262887 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial threes test
Number of subjects: 631
Study 9262887 — intervention group
Group type: EXPERIMENTAL
Intervention: Recitation of months of year in reverse order (MOYR)
Number of subjects: 631
Study 9262887 — intervention group
Group type: COMPARATOR
Intervention: Overall performance
Number of subjects: 631
Study 8261475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin following tissue plasminogen activator (t-PA) administration
Number of subjects: 0
Study 8261475 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy with t-PA
Number of subjects: 0
Study 2858456 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 9
Study 2858456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 9
Study 2858456 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 9
Study 2858456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 28521063 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure messages about toxic products and health effects associated with cigarette constituents
Number of subjects: 388
Study 28521063 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure messages including carcinogenic health effects
Number of subjects: 388
Study 25172877 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated insulin pump system
Number of subjects: 35
Study 25172877 — intervention group
Group type: COMPARATOR
Intervention: Manual BG entry system
Number of subjects: 35
Study 25172877 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated insulin pump system in adolescents with suboptimal baseline BG frequency
Number of subjects: 35
Study 23613806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 grams daily
Number of subjects: 66
Study 23613806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 4 grams daily divided BID
Number of subjects: 66
Study 23613806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (both dosages)
Number of subjects: 66
Study 23613806 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 66
Study 21043366 — intervention group
Group type: EXPERIMENTAL
Intervention: SCE-B 0.3-mg tablets
Number of subjects: 28
Study 21043366 — intervention group
Group type: EXPERIMENTAL
Intervention: SCE-B 1.25-mg tablets
Number of subjects: 28
Study 18035495 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h recall rating of average post-operative pain
Number of subjects: 0
Study 18035495 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak pain
Number of subjects: 0
Study 18035495 — intervention group
Group type: EXPERIMENTAL
Intervention: End pain
Number of subjects: 0
Study 18035495 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak and end pain together
Number of subjects: 0
Study 16793845 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 66
Study 16793845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 14687523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bing Shi Yu Shang ointment
Number of subjects: 200
Study 14687523 — intervention group
Group type: COMPARATOR
Intervention: Jing Wan Hong ointment
Number of subjects: 200
Study 12705106 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction training
Number of subjects: 64
Study 12705106 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study 10481524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal NIPPV and continued LTOT (Group II)
Number of subjects: 19
Study 10481524 — intervention group
Group type: COMPARATOR
Intervention: LTOT only (Group I)
Number of subjects: 19
Study 8942501 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring (monitored group)
Number of subjects: 339
Study 8942501 — intervention group
Group type: COMPARATOR
Intervention: High-risk prenatal care alone (not monitored group)
Number of subjects: 339
Study 1773368 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 20
Study 1773368 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 6762247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural BCG plus oral isoniazid (INH)
Number of subjects: 0
Study 6762247 — intervention group
Group type: COMPARATOR
Intervention: Intrapleural saline plus oral placebo
Number of subjects: 0
Study 6762247 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial white count and neutrophil count elevations
Number of subjects: 0
Study 6762247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 29 degrees C T cell rosette index
Number of subjects: 0
Study 6762247 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial immunological tests
Number of subjects: 0
Study 30696573 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg daily from enrolment prepregnancy until 20 weeks' gestation)
Number of subjects: 1355
Study 30696573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg daily from enrolment prepregnancy until 20 weeks' gestation)
Number of subjects: 1355
Study 30696573 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg daily) with compliance >80%
Number of subjects: 1355
Study 30696573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg daily) with compliance >80%
Number of subjects: 1355
Study 27435048 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy (ACRT) consisting of two cycles of chemotherapy (5‐fluorouracil and cisplatin) and radiotherapy; administered alternately over weeks 1-7
Number of subjects: 28
Study 27435048 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy (ACRT)
Number of subjects: 28
Study 27022822 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued thienopyridine plus aspirin (18 months)
Number of subjects: 19684
Study 27022822 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin (18 months)
Number of subjects: 19684
Study 25141111 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled medial branch block
Number of subjects: 54
Study 25141111 — intervention group
Group type: COMPARATOR
Intervention: Sham blockade (saline injection)
Number of subjects: 54
Study 22607852 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment decisions guided by central BP estimated using radial tonometry
Number of subjects: 284
Study 22607852 — intervention group
Group type: COMPARATOR
Intervention: Usual care based on office, home, and 24‐hour ambulatory brachial BP
Number of subjects: 284
Study 19411100 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rivaroxaban 10 mg once daily
Number of subjects: 3148
Study 19411100 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin 30 mg every 12 h
Number of subjects: 3148
Study 17548111 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (three 15‐min massages each day for 5 consecutive days)
Number of subjects: 0
Study 17548111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 16340050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil massage
Number of subjects: 0
Study 16340050 — intervention group
Group type: COMPARATOR
Intervention: Massage without oil
Number of subjects: 0
Study 16340050 — intervention group
Group type: COMPARATOR
Intervention: No massage
Number of subjects: 0
Study 12473805 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg twice daily for 3 days
Number of subjects: 531
Study 12473805 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg twice daily for 5 days
Number of subjects: 531
Study 12473805 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir treatment initiated within 6 hours of first sign or symptom
Number of subjects: 531
Study 10075224 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion (600 mg of mifepristone followed by 400 microg of misoprostol after 48 h)
Number of subjects: 500
Study 10075224 — intervention group
Group type: COMPARATOR
Intervention: Surgical abortion
Number of subjects: 500
Study 10075224 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion (adolescents)
Number of subjects: 500
Study 7926971 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 micrograms/kg subcutaneously)
Number of subjects: 23
Study 7926971 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (10 micrograms/kg in a 6-h IV infusion)
Number of subjects: 23
Study 7926971 — intervention group
Group type: COMPARATOR
Intervention: Control (no growth factors)
Number of subjects: 23
Study 2508502 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (MT, 10 mg/kg)
Number of subjects: 0
Study 2508502 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (PR, 40 mg/kg)
Number of subjects: 0
Study 2508502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 775883 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.025 mg/kg)
Number of subjects: 32
Study 775883 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.05 mg/kg)
Number of subjects: 32
Study 775883 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 32
Study 775883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31034316 — intervention group
Group type: EXPERIMENTAL
Intervention: Protonics™ knee brace
Number of subjects: 41
Study 31034316 — intervention group
Group type: COMPARATOR
Intervention: Sport cord
Number of subjects: 41
Study 29389471 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage (15-min, twice a day for three days)
Number of subjects: 70
Study 29389471 — intervention group
Group type: COMPARATOR
Intervention: Routine cares
Number of subjects: 70
Study 26398685 — intervention group
Group type: EXPERIMENTAL
Intervention: 175 μg of intravitreal ocriplasmin injection
Number of subjects: 22
Study 26398685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 25767804 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative virtual design and assisted operation (virtual group)
Number of subjects: 32
Study 25767804 — intervention group
Group type: COMPARATOR
Intervention: Direct open reduction and internal fixation (control group)
Number of subjects: 32
Study 22417767 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 21